Roivant Sciences Statistics
Want to see ROIV full AI Analyst Report?
Roivant Sciences (ROIV) Stock Statistics & Valuation Metrics
Total Valuation
Roivant Sciences has a market cap or net worth of $30.32B. The enterprise value is $22.91B.
- Market Cap
- $30.32B
- Enterprise Value
- $22.91B
Share Statistics
Roivant Sciences has 724,561,460 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 724,561,460
- Owned by Insiders
- 16.77%
- Owned by Institutions
- 41.04%
Financial Efficiency
Roivant Sciences’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -23.63%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.05
- Return on Invested Capital (ROIC)
- -23.63%
- Return on Capital Employed (ROCE)
- -0.24
- Revenue Per Employee
- 11.46K
- Profits Per Employee
- -415.77K
- Employee Count
- 721
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Roivant Sciences is -83.74. Roivant Sciences’s PEG ratio is 0.75.
- PE Ratio
- -83.74
- PS Ratio
- 708.95
- PB Ratio
- 7.23
- Price to FCF
- -1110.28
- Price to Operating Cash Flow
- -992.25
- PEG Ratio
- 0.75
Income Statement
In the last 12 months, Roivant Sciences had revenue of 8.26M and earned -299.77M in profits. Earnings per share was -0.43.
- Revenue
- 8.26M
- Gross Profit
- 6.97M
- Operating Income
- -1.29B
- Pretax Income
- -264.58M
- Net Income
- -299.77M
- EBITDA
- -261.23M
- Earnings Per Share (EPS)
- -0.43
Cash Flow
In the last 12 months, operating cash flow was -29.28M and capital expenditures 3.05M, giving a free cash flow of -26.23M billion.
- Operating Cash Flow
- -29.28M
- Free Cash Flow
- -26.23M
- Free Cash Flow per Share
- -0.04
Dividends & Yields
Roivant Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.09%
- Earnings Yield
- -1.19%
Stock Price Statistics
- Beta
- 0.80
- 52-Week Price Change
- 87.57%
- 50-Day Moving Average
- 36.95
- 200-Day Moving Average
- 32.22
- Relative Strength Index (RSI)
- 68.03
- Average Volume (3m)
- 8.08M
Important Dates
Roivant Sciences upcoming earnings date is Feb 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Feb 15, 2027
- Ex-Dividend Date
- ―
Financial Position
Roivant Sciences as a current ratio of 18.37, with Debt / Equity ratio of 2.37%
- Current Ratio
- 18.37
- Quick Ratio
- 18.37
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 5.02
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Roivant Sciences has paid 133.33M in taxes.
- Income Tax
- 133.33M
- Effective Tax Rate
- -0.50
Enterprise Valuation
Roivant Sciences EV to EBITDA ratio is -93.08, with an EV/FCF ratio of -1045.48.
- EV to Sales
- 667.57
- EV to EBITDA
- -93.08
- EV to Free Cash Flow
- -1045.48
- EV to Operating Cash Flow
- -936.68
Balance Sheet
Roivant Sciences has $4.21B in cash and marketable securities with $106.57M in debt, giving a net cash position of $4.10B billion.
- Cash & Marketable Securities
- $4.21B
- Total Debt
- $106.57M
- Net Cash
- $4.10B
- Net Cash Per Share
- $5.66
- Tangible Book Value Per Share
- $6.36
Margins
Gross margin is 88.68%, with operating margin of -3233.02%, and net profit margin of -838.19%.
- Gross Margin
- 88.68%
- Operating Margin
- -3233.02%
- Pretax Margin
- -723.38%
- Net Profit Margin
- -838.19%
- EBITDA Margin
- -717.22%
- EBIT Margin
- -723.38%
Analyst Forecast
The average price target for Roivant Sciences is $49.18, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $49.18
- Price Target Upside
- 22.99% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- 102.09%
- EPS Growth Forecast
- 9.46%
Scores
- Smart Score
- 10
- AI Score
- 67
